[ad_1]
However, the situation in the media market is constantly changing: if you want to support quality business journalism and want to be part of the Portfolio community, subscribe to Portfolio Signature articles. Know more
A senior official of the state-owned CNBG, speaking to Chinese state radio, also reported that the manufacturer’s two products, which are still being tested, could provide protection for up to three years.
The two vaccines are in the third phase of clinical trials, and are being tested in a larger number of test subjects in the United Arab Emirates, Bahrain, Peru, Morocco, Argentina and Jordan, among others.
Under China’s emergency program, which also allows the products under test to be administered to those most at risk of infection, such as healthcare workers, two CNBG products have been used more widely to date.
There are eight coronavirus vaccines in the third phase of clinical trials around the world, four of which have been developed by Chinese companies.
Of the four Chinese vaccines, three were approved for civilian use under the emergency program: two CNBG and a Sinovac formulation called CoronaVac. The fourth, a vaccine called CanSino, developed by the Chinese Academy of Military Medicine, was licensed by the military. The drug was administered to Chinese soldiers participating in peacekeeping operations in countries severely affected by the epidemic. Sinovac announced Sunday that it also vaccinated its workers and families, nearly 3,000 people, with its own vaccine. CNBG also used its vaccines among its own employees and announced last week that it had signed an agreement with Chinese telecommunications giant Huawei to supply vaccines to its workers.
And the Chinese news site Caixin reported that several Chinese state-owned companies are already using the experimental drugs among their employees.
CNBG has established two facilities, one in Beijing and one in Wuhan, known as the first virus center, to produce vaccines. The capacity of the production lines will exceed 220 million doses per year, but could reach up to one billion per year if completed with the expansion of the facilities.
Sinovac started CoronaVac production in late August and reported a capacity of 300 million doses per year.
Cover image: Getty Images
[ad_2]
